Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the ...

The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of ...

Presbyopia has an impact on about half of the Japanese population aged 40 years or older. Presbyopia is diagnosed by subjective tests, and is not assessed quantitatively. In addition, appropriate ...

Opus Genetics and Viatris, Inc. (Viatris) (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for ...

Johnson & Johnson professional education and development manager, David Jameson, discusses the current options in a ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Presbyopia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

The performance of visual functions decreases as one ages. With at least two billion people affected globally, presbyopia is the world’s leading cause of visual loss. One-third of India’s population ...

The optical formula for IOL presbyopia correction is a familiar one. It is no different than the formula for a successful spectacle presbyopia correction — emmetropia plus the reading “add.” ...

Phentolamine ophthalmic solution 0.75% shows significant near vision improvement in patients with presbyopia during the phase 3 VEGA-3 clinical trial.

US FDA accepts Viatris’ sNDA of MR-141 to review for treatment of presbyopia: Pittsburgh Saturday, February 28, 2026, 12:00 Hrs [IST] Viatris Inc, US-headquartered global health ...